Information about GlobalPharmacyMeds.to
List of countries where we can ship Osimertinib:
Latest news releases on Osimertinib:
Discover the new first-line TAGRISSO efficacy (PFS) data in NSCLC and access information about safety, MOA, dosing, AURA3 and other resources
Anwendungsgebiet gemäß Fachinformation für Osimertinib (Tagrisso®) Tagrisso ist angezeigt zur Behandlung von erwachsenen Patienten mit lokal fortgeschrittenem ...
On April 18, 2018, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) for the first-line treatment of patients with ...
Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations ...
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Results from exploratory trial of evaluation of combination treatment
Editorial from The New England Journal of Medicine — Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung Cancer
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited
The FDA approved its use with tissue or plasma biopsies, giving clinicians a non-invasive option to conduct a test that provides results in a day.
Learn about TAGRISSO® (osimertinib), a once-daily prescription treatment for people with metastatic non-small cell lung cancer (NSCLC) with abnormal EGFR genes.